- Home
- AIRI vs CURX Comparison
AIRI vs CURX Comparison
Compare AIRI & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRI | CURX |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 12.4M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AIRI | CURX |
|---|---|---|
| Price | $3.05 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.3K | ★ 89.2K |
| Earning Date | 05-14-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.55 | $0.26 |
| 52 Week High | $4.17 | $9.18 |
Technical Indicators
Market Signals| Indicator | AIRI | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 43.59 |
| Support Level | $2.98 | $0.32 |
| Resistance Level | $3.37 | $0.41 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 77.59 | 38.74 |
Price Performance
Historical ComparisonAbout AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.